Concepts (251)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myasthenia Gravis | 8 | 2022 | 83 | 3.570 |
Why?
|
| Amyloid Neuropathies, Familial | 4 | 2022 | 25 | 2.740 |
Why?
|
| Amyotrophic Lateral Sclerosis | 11 | 2020 | 182 | 2.160 |
Why?
|
| Cardiomyopathies | 2 | 2022 | 240 | 1.430 |
Why?
|
| Polyneuropathies | 2 | 2023 | 27 | 1.290 |
Why?
|
| Thymectomy | 3 | 2022 | 31 | 1.190 |
Why?
|
| Peripheral Nervous System Diseases | 4 | 2017 | 85 | 1.170 |
Why?
|
| Thymoma | 3 | 2020 | 30 | 1.050 |
Why?
|
| Thymus Neoplasms | 3 | 2020 | 41 | 1.040 |
Why?
|
| Machado-Joseph Disease | 1 | 2023 | 8 | 0.940 |
Why?
|
| Diabetic Neuropathies | 1 | 2023 | 40 | 0.920 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2020 | 66 | 0.870 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2023 | 73 | 0.860 |
Why?
|
| Mononeuropathies | 1 | 2022 | 8 | 0.850 |
Why?
|
| Steroids | 2 | 2022 | 177 | 0.850 |
Why?
|
| Compartment Syndromes | 1 | 2021 | 12 | 0.800 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2023 | 225 | 0.790 |
Why?
|
| Rhabdomyolysis | 1 | 2021 | 28 | 0.790 |
Why?
|
| Low Back Pain | 1 | 2021 | 40 | 0.770 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2020 | 52 | 0.740 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2020 | 81 | 0.720 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2019 | 16 | 0.700 |
Why?
|
| Facial Paralysis | 1 | 2019 | 17 | 0.690 |
Why?
|
| Facial Nerve | 1 | 2019 | 33 | 0.670 |
Why?
|
| Muscle, Skeletal | 3 | 2022 | 449 | 0.670 |
Why?
|
| Motor Neuron Disease | 2 | 2020 | 21 | 0.650 |
Why?
|
| Influenza Vaccines | 1 | 2019 | 142 | 0.640 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 261 | 0.640 |
Why?
|
| Humans | 47 | 2023 | 86601 | 0.630 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2023 | 567 | 0.630 |
Why?
|
| Late Onset Disorders | 1 | 2017 | 3 | 0.610 |
Why?
|
| Spinal Stenosis | 1 | 2017 | 26 | 0.600 |
Why?
|
| Head Movements | 1 | 2017 | 39 | 0.590 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 199 | 0.580 |
Why?
|
| Vital Capacity | 1 | 2016 | 64 | 0.580 |
Why?
|
| Enteral Nutrition | 1 | 2016 | 102 | 0.570 |
Why?
|
| Male | 30 | 2023 | 40956 | 0.560 |
Why?
|
| Gastrostomy | 1 | 2016 | 69 | 0.560 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2019 | 382 | 0.520 |
Why?
|
| Pneumothorax | 1 | 2015 | 52 | 0.520 |
Why?
|
| Hepatitis C | 1 | 2017 | 208 | 0.510 |
Why?
|
| Aged | 18 | 2023 | 18402 | 0.510 |
Why?
|
| Melanoma | 1 | 2019 | 454 | 0.510 |
Why?
|
| Diaphragm | 1 | 2014 | 50 | 0.500 |
Why?
|
| Catheterization, Central Venous | 1 | 2015 | 116 | 0.490 |
Why?
|
| Respiration Disorders | 1 | 2014 | 39 | 0.490 |
Why?
|
| Middle Aged | 22 | 2021 | 25017 | 0.490 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1267 | 0.470 |
Why?
|
| Immunotherapy | 1 | 2019 | 629 | 0.470 |
Why?
|
| Spinal Curvatures | 1 | 2013 | 7 | 0.460 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 1376 | 0.450 |
Why?
|
| Spinal Cord Diseases | 1 | 2013 | 29 | 0.450 |
Why?
|
| Muscular Diseases | 1 | 2013 | 63 | 0.440 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 556 | 0.440 |
Why?
|
| Prealbumin | 2 | 2022 | 34 | 0.430 |
Why?
|
| Neuromuscular Diseases | 1 | 2012 | 30 | 0.420 |
Why?
|
| Venous Thrombosis | 1 | 2014 | 243 | 0.410 |
Why?
|
| Spinal Cord | 1 | 2013 | 249 | 0.400 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2011 | 107 | 0.390 |
Why?
|
| Postoperative Complications | 2 | 2022 | 2207 | 0.390 |
Why?
|
| Glucose Intolerance | 1 | 2011 | 96 | 0.370 |
Why?
|
| Female | 22 | 2023 | 44507 | 0.370 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 150 | 0.370 |
Why?
|
| Lymphoma | 1 | 2011 | 262 | 0.360 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 1169 | 0.360 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 141 | 0.350 |
Why?
|
| Alzheimer Disease | 1 | 2013 | 470 | 0.340 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 159 | 0.330 |
Why?
|
| Pain | 1 | 2011 | 391 | 0.320 |
Why?
|
| Pyridostigmine Bromide | 3 | 2020 | 11 | 0.320 |
Why?
|
| Insulin | 2 | 2023 | 1160 | 0.310 |
Why?
|
| Diagnosis, Differential | 5 | 2020 | 1565 | 0.300 |
Why?
|
| Tarlov Cysts | 1 | 2006 | 1 | 0.300 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 2 | 2004 | 10 | 0.300 |
Why?
|
| Depression | 1 | 2011 | 473 | 0.300 |
Why?
|
| Electromyography | 4 | 2020 | 183 | 0.290 |
Why?
|
| Mutation | 3 | 2022 | 3967 | 0.290 |
Why?
|
| Central Nervous System Diseases | 1 | 2006 | 52 | 0.280 |
Why?
|
| Demyelinating Diseases | 1 | 2006 | 68 | 0.280 |
Why?
|
| Prednisone | 2 | 2020 | 258 | 0.270 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 930 | 0.270 |
Why?
|
| Neural Conduction | 2 | 2023 | 69 | 0.250 |
Why?
|
| Ceftriaxone | 2 | 2014 | 9 | 0.240 |
Why?
|
| Remission Induction | 2 | 2019 | 722 | 0.240 |
Why?
|
| Immunity, Cellular | 2 | 2020 | 177 | 0.240 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 1056 | 0.240 |
Why?
|
| Penetrance | 1 | 2003 | 44 | 0.230 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 2 | 2015 | 9 | 0.230 |
Why?
|
| Ophthalmoplegia, Chronic Progressive External | 1 | 2023 | 2 | 0.230 |
Why?
|
| Bell Palsy | 1 | 2023 | 3 | 0.230 |
Why?
|
| Retrospective Studies | 4 | 2022 | 8475 | 0.230 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 2022 | 9 | 0.230 |
Why?
|
| Technetium | 1 | 2022 | 28 | 0.220 |
Why?
|
| Diphosphates | 1 | 2022 | 18 | 0.220 |
Why?
|
| Recurrence | 2 | 2019 | 1139 | 0.220 |
Why?
|
| Age of Onset | 1 | 2003 | 310 | 0.220 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 6501 | 0.220 |
Why?
|
| Superoxide Dismutase | 1 | 2003 | 177 | 0.220 |
Why?
|
| Muscle Weakness | 2 | 2017 | 61 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2020 | 3352 | 0.210 |
Why?
|
| Immunologic Factors | 2 | 2020 | 170 | 0.210 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2020 | 45 | 0.210 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2021 | 28 | 0.200 |
Why?
|
| Paraspinal Muscles | 1 | 2021 | 1 | 0.200 |
Why?
|
| Cerebellum | 1 | 2023 | 247 | 0.200 |
Why?
|
| Lumbosacral Region | 1 | 2021 | 25 | 0.200 |
Why?
|
| Sulfonamides | 1 | 2023 | 300 | 0.190 |
Why?
|
| Meningitis | 1 | 2020 | 20 | 0.190 |
Why?
|
| Disease Models, Animal | 2 | 2006 | 2232 | 0.190 |
Why?
|
| Jews | 1 | 2020 | 42 | 0.190 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2020 | 18 | 0.190 |
Why?
|
| Lumbar Vertebrae | 1 | 2021 | 148 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 170 | 0.180 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2020 | 122 | 0.180 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 151 | 0.180 |
Why?
|
| Iodine Radioisotopes | 1 | 2020 | 134 | 0.180 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2020 | 100 | 0.180 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 115 | 0.180 |
Why?
|
| Treatment Outcome | 5 | 2022 | 7988 | 0.180 |
Why?
|
| Thyroidectomy | 1 | 2020 | 170 | 0.170 |
Why?
|
| Heterozygote | 1 | 2020 | 365 | 0.170 |
Why?
|
| Ipilimumab | 1 | 2019 | 58 | 0.170 |
Why?
|
| Adult | 11 | 2020 | 25640 | 0.170 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2020 | 156 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 2 | 2014 | 746 | 0.160 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 365 | 0.160 |
Why?
|
| Cryoglobulinemia | 1 | 2017 | 6 | 0.160 |
Why?
|
| Glucocorticoids | 1 | 2020 | 352 | 0.160 |
Why?
|
| Sural Nerve | 1 | 2017 | 19 | 0.160 |
Why?
|
| Vasculitis | 1 | 2017 | 38 | 0.150 |
Why?
|
| Cervical Cord | 1 | 2017 | 6 | 0.150 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 250 | 0.150 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2017 | 16 | 0.150 |
Why?
|
| Visual Analog Scale | 1 | 2016 | 14 | 0.150 |
Why?
|
| Biopsy | 1 | 2020 | 1161 | 0.140 |
Why?
|
| Gout | 1 | 2017 | 76 | 0.140 |
Why?
|
| Arm | 1 | 2017 | 91 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 2436 | 0.140 |
Why?
|
| B-Lymphocytes, Regulatory | 1 | 2016 | 8 | 0.140 |
Why?
|
| Electroencephalography | 1 | 2020 | 707 | 0.140 |
Why?
|
| Prospective Studies | 2 | 2023 | 4210 | 0.140 |
Why?
|
| Biomarkers | 1 | 2022 | 1718 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 532 | 0.140 |
Why?
|
| Plasmapheresis | 1 | 2015 | 26 | 0.130 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 408 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 763 | 0.130 |
Why?
|
| Stroke | 1 | 2023 | 965 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 878 | 0.120 |
Why?
|
| Migraine without Aura | 1 | 2013 | 1 | 0.110 |
Why?
|
| Sumatriptan | 1 | 2013 | 2 | 0.110 |
Why?
|
| Myokymia | 1 | 2013 | 3 | 0.110 |
Why?
|
| Metoclopramide | 1 | 2013 | 16 | 0.110 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1019 | 0.110 |
Why?
|
| Valproic Acid | 1 | 2013 | 24 | 0.110 |
Why?
|
| Neuralgia | 1 | 2013 | 28 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2016 | 1538 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 744 | 0.110 |
Why?
|
| Age Factors | 1 | 2017 | 1849 | 0.110 |
Why?
|
| Cytokines | 1 | 2016 | 776 | 0.110 |
Why?
|
| Psychomotor Agitation | 1 | 2012 | 26 | 0.100 |
Why?
|
| 2-Chloroadenosine | 1 | 2011 | 5 | 0.100 |
Why?
|
| Blindness | 1 | 2012 | 41 | 0.100 |
Why?
|
| Video Recording | 1 | 2013 | 190 | 0.100 |
Why?
|
| Status Epilepticus | 1 | 2012 | 31 | 0.100 |
Why?
|
| Coma | 1 | 2012 | 44 | 0.100 |
Why?
|
| Analgesics | 1 | 2013 | 119 | 0.100 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2011 | 10 | 0.100 |
Why?
|
| Deoxyadenosines | 1 | 2011 | 23 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 78 | 0.100 |
Why?
|
| Dyspnea | 1 | 2012 | 73 | 0.100 |
Why?
|
| Rituximab | 1 | 2011 | 116 | 0.100 |
Why?
|
| Lymphoma, Follicular | 1 | 2011 | 70 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2011 | 293 | 0.100 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 299 | 0.100 |
Why?
|
| Cyclosporine | 1 | 2011 | 234 | 0.100 |
Why?
|
| Prognosis | 2 | 2020 | 3674 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2017 | 2767 | 0.090 |
Why?
|
| Ubiquinone | 1 | 2009 | 10 | 0.090 |
Why?
|
| Research Design | 1 | 2013 | 594 | 0.090 |
Why?
|
| Aphasia | 1 | 1989 | 14 | 0.090 |
Why?
|
| Terbutaline | 1 | 2008 | 16 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2019 | 3241 | 0.080 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2008 | 72 | 0.080 |
Why?
|
| Hypertension | 1 | 2017 | 1141 | 0.080 |
Why?
|
| Feedback | 1 | 1989 | 133 | 0.080 |
Why?
|
| Antioxidants | 1 | 2009 | 223 | 0.080 |
Why?
|
| Double-Blind Method | 4 | 2020 | 1823 | 0.080 |
Why?
|
| Adolescent | 5 | 2020 | 8979 | 0.080 |
Why?
|
| Hypesthesia | 1 | 2006 | 15 | 0.070 |
Why?
|
| Neurologic Examination | 1 | 2006 | 118 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 2887 | 0.070 |
Why?
|
| Communication | 1 | 1989 | 440 | 0.070 |
Why?
|
| Creatine | 1 | 2004 | 23 | 0.060 |
Why?
|
| Valine | 1 | 2003 | 69 | 0.060 |
Why?
|
| Antibody Formation | 1 | 2004 | 171 | 0.060 |
Why?
|
| Alanine | 1 | 2003 | 85 | 0.060 |
Why?
|
| Family Health | 1 | 2003 | 162 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2020 | 2818 | 0.060 |
Why?
|
| Potassium Channels, Voltage-Gated | 2 | 2015 | 122 | 0.060 |
Why?
|
| Spinal Nerve Roots | 1 | 2002 | 17 | 0.060 |
Why?
|
| Neurofibromatoses | 1 | 2002 | 9 | 0.060 |
Why?
|
| Patients | 1 | 2023 | 100 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2003 | 526 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 39 | 0.050 |
Why?
|
| Exons | 1 | 2003 | 450 | 0.050 |
Why?
|
| Pedigree | 1 | 2003 | 966 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 879 | 0.050 |
Why?
|
| Muscle Strength | 1 | 2020 | 31 | 0.050 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2020 | 21 | 0.050 |
Why?
|
| Brain Stem | 1 | 2020 | 165 | 0.050 |
Why?
|
| Young Adult | 3 | 2020 | 5974 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 196 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 263 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 894 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 2600 | 0.040 |
Why?
|
| Receptors, Cholinergic | 1 | 2016 | 76 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 1801 | 0.030 |
Why?
|
| Animals | 2 | 2006 | 26581 | 0.030 |
Why?
|
| Isaacs Syndrome | 1 | 2015 | 2 | 0.030 |
Why?
|
| Syringomyelia | 1 | 2015 | 15 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2003 | 2356 | 0.030 |
Why?
|
| Half-Life | 1 | 2014 | 96 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 679 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 3636 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 290 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 429 | 0.030 |
Why?
|
| Serotonin 5-HT1 Receptor Agonists | 1 | 2013 | 4 | 0.030 |
Why?
|
| GABA Agents | 1 | 2013 | 8 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2013 | 62 | 0.030 |
Why?
|
| Dopamine Antagonists | 1 | 2013 | 35 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 117 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 244 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 177 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2013 | 321 | 0.030 |
Why?
|
| Emergencies | 1 | 2012 | 113 | 0.030 |
Why?
|
| Acute Disease | 1 | 2013 | 826 | 0.020 |
Why?
|
| Antibodies | 1 | 2013 | 350 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 172 | 0.020 |
Why?
|
| Random Allocation | 1 | 1989 | 332 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 218 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2009 | 129 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 399 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2008 | 839 | 0.020 |
Why?
|
| Isometric Contraction | 1 | 2004 | 38 | 0.020 |
Why?
|
| Cognition | 1 | 1989 | 570 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 977 | 0.010 |
Why?
|
| Paraparesis | 1 | 2002 | 4 | 0.010 |
Why?
|
| Hypertrophy | 1 | 2002 | 62 | 0.010 |
Why?
|
| Radiculopathy | 1 | 2002 | 15 | 0.010 |
Why?
|
| Time Factors | 1 | 2009 | 5209 | 0.010 |
Why?
|
| Radiography | 1 | 2002 | 813 | 0.010 |
Why?
|